Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04229095 · ClinicalTrials.gov registry record · Phase 2
Medication Development in Alcoholism: Suvorexant Versus Placebo
A Phase 2 study, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT04229095 is a Phase 2 study that has completed, run by The Scripps Research Institute. The registered enrollment target is 26 participants.
The verdict
NCT04229095, a Phase 2 study, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The primary hypotheses under test are that alcohol dependent subjects treated with suvorexant will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo. Suvorexant (Belsomra®) received approval by the FDA in 2014 for treatment of insomnia. To control for any effect of pre-existing sleep disturbance for which suvorexant may be indicated, subjects will be stratified on the basis of a Pittsburgh Sleep Quality Index total score of \> 5 versus \<5. Subjects were also stratified by sex.
Interventions
- DRUG Placebo oral tablet
- DRUG Suvorexant 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2022-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04229095
The ClinicalTrials.gov registry entry for NCT04229095 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04229095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04229095 about?
NCT04229095 is a clinical study titled "Medication Development in Alcoholism: Suvorexant Versus Placebo". The primary hypotheses under test are that alcohol dependent subjects treated with suvorexant will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo. Suvorexant (Bels...
What is the current status of trial NCT04229095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-11-17. Estimated completion is 2022-11-08.
What interventions are being tested in trial NCT04229095?
The interventions under investigation include: Placebo oral tablet (DRUG), Suvorexant 20 mg (DRUG).
Who is sponsoring clinical trial NCT04229095?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.